Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy
Authors:
- 1 July 2013
- journal article
- review article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 201 (1) , 80-96
Abstract
OBJECTIVE. This article focuses on imaging techniques and imaging findings after locoregional and systemic therapy in patients with hepatocellular carcinoma (HCC). We discuss currently available locoregional and systemic therapies for HCC, imaging modalities and protocols used to assess HCC response, criteria for assessing HCC response, imaging appearances of treated HCC, and future directions. CONCLUSION. The evaluation of tumor response after systemic and locoregional therapies is essential in directing management for HCC. An understanding of the various therapeutic strategies and of their posttherapy imaging appearances is essential for accurately assessing treatment response. The evaluation of tumor response should include not only anatomic imaging biomarkers, such as reduction in tumor size, but also tumor enhancement and necrosis.Keywords
This publication has 140 references indexed in Scilit:
- Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival TimesGastroenterology, 2011
- Intraprocedural Transcatheter Intra-arterial Perfusion MRI as a Predictor of Tumor Response to Chemoembolization for Hepatocellular CarcinomaAcademic Radiology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Quality Improvement Guidelines for Radiofrequency Ablation of Liver TumoursCardioVascular and Interventional Radiology, 2009
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Molecular targeted therapies in hepatocellular carcinoma†Hepatology, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002